THE topic of cancer drug labels and how they can be updated more quickly, as well as how the labeling system needs to be reformed was front and center at several panels of the Friends of Cancer Research's annual meeting in Washington, D.C. last week, Regulatory Affairs Professionals Society (RAPS) reports.
Old labelling, generic labels and labelling "frozen in time" were all on the agenda with the FDA explaining it can only update labels when trial data is submitted.
Combination products, common in oncology therapy, were also a major source of labelling concern.
Access the discussion at raps.org.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Nov 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Nov 17
